Evidence for a Lowered Threshold for FDA Approval of Oncologics Based on Single-Arm Phase II Data, Compared to the EMA

Value in Health - United Kingdom
doi 10.1016/j.jval.2014.03.570
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Comparing How Single Arm Phase II Trial Data Can Support Approval of Oncologics by European Health Technology Assessment Bodies

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Correction To: FDA and EMA Biosimilar Approvals

Journal of General Internal Medicine
Internal Medicine
2019English

Correction To: FDA Approval of Angiotensin II for the Treatment of Hypotension in Adults With Distributive Shock

American Journal of Cardiovascular Drugs
MedicineCardiovascular MedicinePharmacologyCardiology
2019English

Optimal Continuous-Monitoring Design of Single-Arm Phase II Trial Based on the Simulated Annealing Method

Contemporary Clinical Trials
MedicinePharmacology
2013English

Pnd115 - A Comparison of Fda and Ema Guidance on Medicines for the Treatment of Alzheimer’s Disease

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Response to FDA Commissioner's Statement on Dsuvia Approval

Addiction
MedicinePsychiatryMental Health
2019English

From the FDA: Panel Recommends Approval of Drug for ALS

Journal of the American Osteopathic Association, The
MedicineAlternative MedicineComplementary
1995English

Obinutuzumab Breaks Through to FDA Approval

Cancer Discovery
Oncology
2013English

FDA Approval of New Drugs

JAMA - Journal of the American Medical Association
Medicine
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy